ITEM 2.02 Results of Operations and Financial Condition.

On February 5, 2013, Myriad Genetics, Inc. ("Myriad" or the "Company") announced its financial results for the three and six months ended December 31, 2012. The earnings release is attached hereto as an exhibit to this Current Report on Form 8-K and is being furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 8.01 Other Events.

In its earnings release dated February 5, 2013, attached hereto as Exhibit 99.1, the Company also announced a new $200 million stock repurchase program. The information in the earnings release under the heading "Myriad Announces New $200 Million Share Repurchase Program" is hereby incorporated by reference into this Item 8.01 of this Current Report on Form 8-K and is being filed pursuant to Item 8.01.

ITEM 9.01 Financial Statements and Exhibits.

(d)

Exhibit Number Description 99.1 Earnings release dated February 5, 2013 for the three and six months ended December 31, 2012.

Page 2

---